Cardiology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Non-diabetic STEMI patients: plasma 5-MTP levels associated with biomarkers of post-MI left ventricular remodeling and damage

Ventricular remodeling following myocardial infarction ( MI ) is closely associated with cyclooxygenase-2 ( COX-2 ) expression. 5-methoxytryptophan ( 5-MTP ) was reported to control COX-2 expression.

A prospective study has investigated the association between 5-MTP and post-myocardial infarction left ventricular remodeling.

26 non-diabetic patients with first-time ST segment elevation myocardial infarction ( STEMI ), and 58 controls were enrolled.

Levels of 5-MTP, N-terminal of pro-brain natriuretic peptide ( NT-proBNP ), aminoterminal propeptide of type III procollagen, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 were measured at day 1, day 3, 3 months, 6 months, and 1 year post-myocardial infarction.
Echocardiography was performed during the acute stage ( within 72h ) and 3 months, 6 months, and 1 year post-MI.

The STEMI patients had a significantly lower plasma 5-MTP level at day 1 which reached a nadir at 3 months post-MI.

The level of 5-MTP at day 3 post-MI was significantly correlated with the level of NT-proBNP 1 year post-MI, suggesting that the level of plasma 5-MTP in the early phase after myocardial infarction may predict subsequent cardiac stress and failure.

Receiver operating characteristic ( ROC ) curve analysis revealed that plasma 5-MTP had the best area under the curve value to predict plasma NT-proBNP 1year post-MI.

Further analysis using net reclassification improvement and integrated discrimination improvement models confirmed that plasma 5-MTP at day 3 post-MI significantly improved the predictive power of each of the parameters.

In non-diabetic STEMI patients, plasma 5-MTP levels were associated with biomarkers of post-MI left ventricular remodeling and damage. ( Xagena )

Lin YH et al, Int J Cardiol 2016;222:895-900